2016
Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer
Hatzis C, Symmans WF, Zhang Y, Gould RE, Moulder SL, Hunt KK, Abu-Khalaf M, Hofstatter EW, Lannin D, Chagpar AB, Pusztai L. Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer. Clinical Cancer Research 2016, 22: 26-33. PMID: 26286912, DOI: 10.1158/1078-0432.ccr-14-3304.Peer-Reviewed Original ResearchConceptsPathologic complete responseRecurrence-free survivalTriple-negative breast cancerSurvival benefitNeoadjuvant trialsNeoadjuvant chemotherapyTrial populationBaseline prognosisBreast cancerOverall survival benefitComplete pathologic responseSignificant survival benefitPostneoadjuvant therapyPCR rateComplete responseImproved survivalPathologic responseSurvival improvementTreatment armsPatient survivalResidual diseaseControl armPrognostic variablesPatientsTrials
2009
Eradication of Axillary Lymph Node Metastases Occurs in 74% of Patients Receiving Neoadjuvant Chemotherapy with Concurrent Trastuzumab for HER2 Positive Breast Cancer.
Dominici L, Negron Gonzalez V, Buzdar A, Lucci A, Mittendorf E, Pusztai L, Krishnamurthy S, Le-Petross H, Babiera G, Bedrosian I, Meric-Bernstam F, Hunt K, Valero V, Kuerer H. Eradication of Axillary Lymph Node Metastases Occurs in 74% of Patients Receiving Neoadjuvant Chemotherapy with Concurrent Trastuzumab for HER2 Positive Breast Cancer. Cancer Research 2009, 69: 1086-1086. DOI: 10.1158/0008-5472.sabcs-09-1086.Peer-Reviewed Original ResearchAxillary pathologic complete responseTrastuzumab-based neoadjuvant chemotherapyPathologic complete responseDisease-free survivalHER2-positive breast cancerHER2-positive diseaseResidual axillary diseaseNeoadjuvant chemotherapyPositive breast cancerAxillary metastasesPCR groupAxillary diseasePositive diseaseBreast cancerComplete axillary lymph node dissectionAxillary lymph node dissectionAxillary lymph node metastasisComplete pathologic responseLymph node dissectionKaplan-Meier methodMajority of patientsKaplan-Meier analysisLymph node metastasisEstrogen receptor statusConcurrent trastuzumabPredictors of tumor progression during neoadjuvant chemotherapy in breast cancer
Caudle A, Gonzalez-Angulo A, Kelly H, Liu P, Pusztai L, Symmans W, Kuerer H, Mittendorf E, Hortobagyi G, Meric-Bernstam F. Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. Journal Of Clinical Oncology 2009, 27: 603-603. DOI: 10.1200/jco.2009.27.15_suppl.603.Peer-Reviewed Original ResearchNeoadjuvant chemotherapyHigh Ki-67High tumor gradeStable diseasePR statusBreast cancerTumor gradeKi-67Negative ERNegative ER/PR statusFirst-line surgical approachSingle comprehensive cancer centerTumor progressionER/PR statusTaxane-based regimensComplete pathologic responseSubset of patientsLymph node metastasisHigher T stageComprehensive cancer centerPre-treatment characteristicsNCT regimenLymphovascular invasionMost patientsPathologic response
2004
Gene Expression Profiles Predict Complete Pathologic Response to Neoadjuvant Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy in Breast Cancer
Ayers M, Symmans W, Stec J, Damokosh A, Clark E, Hess K, Lecocke M, Metivier J, Booser D, Ibrahim N, Valero V, Royce M, Arun B, Whitman G, Ross J, Sneige N, Hortobagyi G, Pusztai L. Gene Expression Profiles Predict Complete Pathologic Response to Neoadjuvant Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy in Breast Cancer. Journal Of Clinical Oncology 2004, 22: 2284-2293. PMID: 15136595, DOI: 10.1200/jco.2004.05.166.Peer-Reviewed Original ResearchConceptsPathologic complete responseBreast cancerNeoadjuvant therapyClinical resultsPredictive valueCompletion of chemotherapySequential weekly paclitaxelComplete pathologic responseNeoadjuvant chemotherapy regimenPercent of patientsPatients' clinical resultsExpected response rateFine-needle aspirationNegative predictive valuePositive predictive valueNeoadjuvant paclitaxelChemotherapy regimenWeekly paclitaxelCyclophosphamide chemotherapyUnselected patientsComplete responsePathologic responseInvasive cancerResponse ratePatientsChange in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response
Rajan R, Poniecka A, Smith TL, Yang Y, Frye D, Pusztai L, Fiterman DJ, Gal‐Gombos E, Whitman G, Rouzier R, Green M, Kuerer H, Buzdar AU, Hortobagyi GN, Symmans WF. Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response. Cancer 2004, 100: 1365-1373. PMID: 15042669, DOI: 10.1002/cncr.20134.Peer-Reviewed Original ResearchConceptsResidual tumor sizeCore needle biopsyNeoadjuvant chemotherapyTumor sizeResection specimensNeedle biopsyBreast carcinomaTumor cellularityClinical responsePathologic responseControl groupDiagnostic core needle biopsyGreatest dimensionPrimary surgical managementResidual primary tumorResidual tumor categoriesComplete pathologic responseWeeks of diagnosisResidual tumor groupEosin-stained tissue sectionsCyclophosphamide chemotherapyPartial responsePathologic assessmentPathologic evaluationPathologic size